BTA 0.00% 57.0¢ biota holdings limited

new resistance study relenza better, page-7

  1. TJW
    716 Posts.
    DANK

    In this article, it only talks about Tamiflu, has an actual scientific study been conducted on Relenza or is the commentators just lump Relenza in with Tamiflu because both are NI.

    Lets be fair, GSK claims Relenza is hard to sell because it is in a powder form. The powder form is purely because it does not a prodrug pathway through the stomach to the infected site. Relenza is designed not be require molecular bending as required for Tamiflu for the blocking of the active site.

    Its not fair to do the test on Tamiflu and lump Relenza in the conclusion.

    Has this study actually used Relenza?


    http://www.medicalnewstoday.com/healthnews.php?newsid=67044

    QUOTE

    Dr Hatakeyama and colleagues took before and after samples from 74 children who were treated with oseltamivir (Tamiflu) in the 2004-2005 Type B flu epidemic in Japan and also from 348 other patients (including 66 adults) who were not treated. The patients were seen at 4 different community hospitals.

    They found:

    -- One child of the 74 (1.4 per cent) who had been treated with oseltamivir (Tamiflu) had a variant of flu virus with reduced drug sensitivity.
    -- Variants with reduced sensitivity in 7 (1.7 per cent) of 422 viruses from the 348 untreated patients.
    -- Of the 7 patients with resistant flu strains, 4 had acquired their infection in the community, and 3 had probably been infected by siblings shedding the mutant strains.

    The researchers concluded that in the population they studied, Influenza type B with reduced sensitivity to these types of drugs do not arise as frequently as type A resistant strains.

    "However, they appear to be transmitted within communities and families, requiring continued close monitoring," they added.

    END QUOTE
 
watchlist Created with Sketch. Add BTA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.